Trials / Withdrawn
WithdrawnNCT01046162
A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions
An Open Label,Crossover,Randomized Study Of Two Periods,Two Treatments,Two Sequences, And A Single Dose Of Two Oral Drug Products Of Alprazolam 2mg (Tafil (r), Product Of Pharmacia& Upjohn S.a De C.v Vs Xanax 2mg, Product Of Pfizer Pharmaceuticals Llc) In Healthy Volunteers In Fasting Conditions
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare bioavailability between formulations of alprazolam in tablets to determine their bioequivalence in terms of rate and magnitude of absorption.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alprazolam | Single tablet |
| DRUG | Alprazolam | Single tablet |
Timeline
- Start date
- 2010-07-15
- Primary completion
- 2010-07-22
- Completion
- 2010-07-22
- First posted
- 2010-01-11
- Last updated
- 2021-01-28
Source: ClinicalTrials.gov record NCT01046162. Inclusion in this directory is not an endorsement.